Appendix B: Priority and vulnerable (high risk) populations

Anti-viral access criteria (in full on Pharmac website)

Symptomatic cases, within first five days of symptom onset and not requiring supplemental oxygen, who are also:

- 65 and over, OR
- Māori and Pacific peoples 50 and over, OR
- 50 and over and not completed primary vaccination, OR
- Immunocompromised, OR
- Down Syndrome, OR
- Sickle cell disease, OR
- 3 or more high-risk medical conditions

Priority populations

- Māori and Pacific Peoples
- Disabled people
- People with severe mental health and addiction issues
- Older people (65 and over); and
- Other inequitably impacted population groups, including:
- Migrant ethnic communities,
- Remote and rural people,
- Rough sleepers,
- People in transitional housing, and
- Those not enrolled in primary practices

Vulnerable populations

- People with high-risk medical conditions (long-term health conditions and/or immunocompromised)
- Older people (65 and over)
- Māori and Pacific people with co-morbidities; and
- People who are pregnant

Clinically High Risk

Includes but not limited to:

- People with underlying severe respiratory disease
- People who require O2 monitoring during their COVID-19 illness
- Socially isolated (lives alone, unable to connect with others through technology, little or no social network support)
- Lack of caregiver support if needed, e.g, the other member of the household may also be unwell and/or have underlying health conditions that means they would be unable to care for the person
- Symptoms/signs of dehydration (due to diarrhoea, vomiting, and/or poor fluid intake)
- Challenges with health literacy or ability to understand treatment recommendations